VIA
SNDX icon

Vident Investment Advisory’s Syndax Pharmaceuticals SNDX Stock Holding History

Vident Investment Advisory’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-106,794
Closed -$1.25M – 820
2017
Q3 		$1.25M Buy
106,794
+3,236
+3% +$39.7K 0.07% 338
2017
Q2 		$1.45M Buy
+103,558
New +$1.18M 0.12% 280

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vident Investment Advisory's SNDX Position: Q4 2017 in Review

Vident Investment Advisory sold out of Syndax Pharmaceuticals (SNDX) in Q4 2017, closing a stake of 106,794 shares — an estimated $1.25M sold.

Vident Investment Advisory first reported a position in SNDX in Q2 2017 and held it in 2 quarters. The position peaked at $1.45M in Q2 2017. 80 funds tracked by Wall St. Rank hold SNDX as of Q4 2017.

  • Vident Investment Advisory reported no remaining Syndax Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Vident Investment Advisory sold 106,794 Syndax Pharmaceuticals shares in Q4 2017, an estimated $1.25M.
  • Vident Investment Advisory first reported a position in Syndax Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Vident Investment Advisory's Syndax Pharmaceuticals position peaked at $1.45M in Q2 2017.
  • 80 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2017.

Based on Vident Investment Advisory's 13F filing for Q4 2017, filed 15 Feb 2018.